The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Dose-ranging study of tesetaxel, a novel oral taxane, administered as second-line therapy at a flat dose to patients with advanced gastric cancer.
J. S. Baker
No relevant relationships to disclose
A. Qureshi
Employment or Leadership Position - Genta
Stock Ownership - Genta
L. Itri
Employment or Leadership Position - Genta (B)
Stock Ownership - Genta (B)
W. Sun
Research Funding - Genta
M. F. Mulcahy
No relevant relationships to disclose
J. A. Ajani
No relevant relationships to disclose